BSPAR Biologics Drugs Registry 

BSPAR (British Society for Paediatric and Adolescent Rheumatologists) has set up a registry of patients with Juvenile Idiopathic Arthritis (JIA) who will be treated with biologics in the United Kingdom and Republic of Ireland in order to monitor the safety and efficacy of these biologics in normal clinical practice (“Patient Registry”). Initially only one biologic (Enbrel® (etanercept)) will be involved, although others may be included as they become available. The data generated by this surveillance study in respect of Enbrel® will be made available to Wyeth, the manufacturer of Enbrel®, so that primarily Wyeth is able to meet its regulatory obligations in relation to Enbrel®.

This site is designed as a source of information for anyone with an interest in understanding more about the Registry and as a portal to an online database that will be used by clinicians to register their Enbrel® patients. There is also a section about the origins and ethos of BSPAR; there is breaking news; useful documents and forms to download, as well as a list of links to other relevant web sites.

This site contains useful information for health care professionals involved in the care of children and adolescents prescribed biologic agents for rheumatic disease. If you wish to know more about BSPAR or register to be a member of BSPAR, please go back to the BSPAR Website: membership is open to all health care professionals in the UK who are involved in the care of children and adolescents with rheumatic disease.

For further information please contact: b.thomas.1@bham.ac.uk or Emily.Sutton@manchester.ac.uk

Continue to BSPAR Biologics Drugs Registry